Letter to the editor

New England Journal of Medicine

Volumn 360, Issue 10, 2009, Pages 1038-1039

  Fugh Berman, Adriane ^a  

^a GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; ROSUVASTATIN; BIOLOGICAL MARKER; FLUOROBENZENE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PYRIMIDINE DERIVATIVE; SULFONAMIDE;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; HUMAN; HYPERTENSION; LETTER; MEDICAL DECISION MAKING; PRIMARY PREVENTION; PRIORITY JOURNAL; RACE DIFFERENCE; RISK ASSESSMENT; UNSPECIFIED SIDE EFFECT; ASIAN; BLOOD; DOSE RESPONSE; METABOLISM; NOTE;

ASIAN CONTINENTAL ANCESTRY GROUP; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CARDIOVASCULAR DISEASES; DOSE-RESPONSE RELATIONSHIP, DRUG; FLUOROBENZENES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; PYRIMIDINES; SULFONAMIDES;

EID: 62349138028     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMc082574     Document Type: Letter

References (3)

1. Lee E, Ryan S, Birmingham B, et al. Rosuvastatin pharmacokinetics and pharmacogenetics in white and Asian subjects residing in the same environment. Clin Pharmacol Ther 2005;78: 330-41.
2. Tirona RG. Ethnic differences in statin disposition. Clin Pharmacol Ther 2005;78:311-6.
3. ChoiJH, Lee MG, Cho JY, LeeJE, Kim KH, ParkK. Influence of OATP1B1 genotype on the pharmacokinetics of rosuvastatin in Koreans. Clin Pharmacol Ther 2008;83:251-7.